Novo Nordisk's Diabetes Drug Outshines Ozempic: Buy?
A new diabetes drug from Novo Nordisk could change the GLP-1 landscape. This deep dive breaks down what investors sho...
Identify compelling low-cost index funds for retirement by evaluating tracking error, fees, and diversification. Build a lineup aligned with long-term goals.
27,243 articlesA new diabetes drug from Novo Nordisk could change the GLP-1 landscape. This deep dive breaks down what investors sho...
Ripple (XRP) traders are eyeing a potential return to its 2025 peak of $3.65, even as the token trades near $1.45. Ke...
U.S. and Japanese banks show divergent moves on XRP. Goldman Sachs dumped its XRP positions, Morgan Stanley added a t...
When a top executive sells a large block of stock, investors want to know whether it signals trouble or simply person...
MercadoLibre fell in February amid margin concerns and tougher competition in LATAM. This article breaks down the for...
The CSWC 2026 earnings transcript offers a clear read on the company’s income engine, credit quality, and capital str...
Insider moves often spark questions when a stock rallies. This article examines Nayax's CMO sale during a solid run, ...
Hyperion, a public hyperliquid treasury firm, announces a 500,000 HYPE token deal with Skew under a HAUS agreement, e...
A senior executive recently reduced his stake in CATY by one third through an open market sale. This article explains...
A prominent investor placed a sizable stake in Nektar Therapeutics, sparking questions about the stock's potential. T...
Cerebras stock is catching attention this week as analysts initiate coverage and AI demand grows. This article breaks...
When a PayPal vice president sold a large block of stock, investors naturally wonder what it signals. This guide brea...